Cyclosporine-induced hypertension in cardiac transplantation

Med Clin North Am. 1997 Nov;81(6):1347-57. doi: 10.1016/s0025-7125(05)70587-3.

Abstract

Cyclosporine-induced hypertension occurs in more than 90% of patients following cardiac transplantation. This article underlines the clinical characteristics as well as the mechanisms that can be associated with the development of cyclosporine-induced hypertension. In addition, the clinical trials up to date for the treatment of hypertension following cardiac transplantation are discussed. However, in view of the possible long-term sequelae associated with cyclosporine-induced hypertension, further studies to evaluate the long-term efficacy and safety of antihypertensive agents and finally the long-term effects of hypertension on the cardiac allograft are needed.

Publication types

  • Review

MeSH terms

  • Antihypertensive Agents / therapeutic use
  • Clinical Trials as Topic
  • Cyclosporine / adverse effects*
  • Heart Transplantation*
  • Humans
  • Hypertension / chemically induced*
  • Hypertension / drug therapy
  • Postoperative Complications / chemically induced*
  • Postoperative Complications / drug therapy
  • Sympathetic Nervous System / drug effects

Substances

  • Antihypertensive Agents
  • Cyclosporine